HIGHLIGHTS
- who: January and colleagues from the Shanghai Tong University, China have published the paper: Flat dose regimen of toripalimab based on model-informed drug development approach, in the Journal: (JOURNAL)
- what: The aim of this study is to provide pharmacological evidence for a flat dosing regimen of toripalimab by assessing the efficacy and safety profile of a 240 mg Q3W flat dose relative to the currently approved 3 mg/kg Q2W. The aim of this study was to provide pharmacokinetic evidence supporting flat dosage of toripalimab in antitumor therapy. Such a structure was deemed suitable . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.